EFFECT OF ALPROSTADIL ON SERUM P-SELECTIN, PLACENTAL GROWTH FACTOR AND MATRIX METALLOPROTEINASE-9 IN PATIENTS WITH ACUTE CORONARY SYNDROME

Objective: To study the effect of alprostadil on serum P-selectin, placental growth factor and matrix metalloproteinase-9 in patients with acute coronary syndrome. Methods: A total of 840 patients diagnosed with acute coronary syndrome after coronary angiography in our department, including 378 patients with stable angina pectoris (SAP), 264 patients with unstable angina pectoris (UAP) and 198 patients with acute myocardial infarction (AMI), were enrolled in this study within the period March 2016 to December 2016. They were divided into two groups according to the random number grouping method: observation group and control group. Those in the control group were given the conventional treatment of anti-thrombosis and anticoagulant therapy, whereas those in the observation group were treated with conventional treatment plus alprostadil twice a day for one week. The differences serum P-selectin, placental growth factor and matrix metalloproteinase-9 were compared between the three types of patients, and the changes of various indicators before and after treatment with alprostadil were analysed. Results: The concentrations of serum P-selectin, placental growth factor and matrix metalloproteinase-9 in SAP, UAP and AMI patients were statistically significant (P<0.05) and significantly lower than those before treatment (P<0.05) and those in the same control group (P<0.05). Conclusion: Alprostadil has a good inhibitory effect on the expression of serum P-selectin, placental growth factor and matrix metalloproteinase-9 in patients with acute coronary syndrome, effectively reducing their concentrations significantly.